PAVmed Inc. Stock

Equities

PAVM

US70387R4039

Advanced Medical Equipment & Technology

Delayed Nasdaq 03:14:13 2024-06-10 pm EDT 5-day change 1st Jan Change
1.16 USD 0.00% Intraday chart for PAVmed Inc. -17.14% -71.84%
Sales 2024 * 5.74M Sales 2025 * 18.36M Capitalization 10.94M
Net income 2024 * -62M Net income 2025 * -53M EV / Sales 2024 * 1.91 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 0.6 x
P/E ratio 2024 *
-0.19 x
P/E ratio 2025 *
-0.45 x
Employees 107
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.72%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.65%
1 week-20.00%
Current month-20.00%
1 month-48.44%
3 months-57.51%
6 months-60.81%
Current year-71.84%
More quotes
1 week
1.10
Extreme 1.095
1.47
1 month
1.10
Extreme 1.095
2.35
Current year
1.10
Extreme 1.095
4.29
1 year
1.10
Extreme 1.095
9.00
3 years
1.10
Extreme 1.095
145.50
5 years
1.10
Extreme 1.095
145.50
10 years
1.10
Extreme 1.095
228.60
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 14-06-25
Director of Finance/CFO 67 17-03-20
Chief Tech/Sci/R&D Officer - 21-10-20
Members of the board TitleAgeSince
Director/Board Member 81 14-12-31
Director/Board Member 69 14-12-31
Director/Board Member 62 21-04-21
More insiders
Date Price Change Volume
24-06-10 1.16 0.00% 24 045
24-06-07 1.16 +2.65% 55,992
24-06-06 1.13 -4.24% 115,462
24-06-05 1.18 -8.53% 49,671
24-06-04 1.29 -7.86% 47,608

Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT

More quotes
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is focused on enhanced personalized cancer care through remote patient monitoring using implantable vascular access port with wireless communication combined with an oncologist-designed remote digital healthcare platform.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
1.16 USD
Average target price
15.5 USD
Spread / Average Target
+1,236.21%
Consensus